# Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

> clinical trial · VERIFIED · 2026-07-30

Status: ACTIVE_NOT_RECRUITING · Sponsor: Children's Oncology Group · Condition: Recurrent B Acute Lymphoblastic Leukemia

- Company: Children's Oncology Group
- Sector: Recurrent B Acute Lymphoblastic Leukemia
- Primary source: https://clinicaltrials.gov/study/NCT02981628

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.